Y-box binding protein-1 expression in diffuse large B-cell lymphoma: an impact on prognosis in the rituximab era

References

• Coiffier B, Lepage E, Briere J, et al CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–1947.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275–282.
   PubMed Web of Science ®Google Scholar
• Prichard M, Harris T, Williams ME, Densmore JJ. Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma. Expert Opin Pharmacother 2009;10:983–995.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS, et al Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313–2323.
   PubMed Web of Science ®Google Scholar
• Kuwano M, Uchiumi T, Hayakawa H, et al The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Sci 2003;94:9–14.
   PubMed Web of Science ®Google Scholar
• Bae W, Jones PG, Inouye M. CspA, the major cold shock protein of Escherichia coli, negatively regulates its own gene expression. J Bacteriol 1997;179:7081–7088.
   PubMed Web of Science ®Google Scholar
• Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays 2003;25:691–698.
   PubMed Web of Science ®Google Scholar
• Evdokimova V, Ovchinnikov LP, Sorensen PH. Y-box binding protein 1: providing a new angle on translational regulation. Cell Cycle 2006;5:1143–1147.
   PubMed Web of Science ®Google Scholar
• Koike K, Uchiumi T, Ohga T, et al Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett 1997;417:390–394.
   PubMed Web of Science ®Google Scholar
• Bargou RC, Jurchott K, Wagener C, et al Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997;3:447–450.
   PubMed Web of Science ®Google Scholar
• Fujii T, Kawahara A, Basaki Y, et al Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers. Cancer Res 2008;68:1504–1512.
   PubMed Web of Science ®Google Scholar
• Saji H, Toi M, Saji S, Koike M, Kohno K, Kuwano M. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma. Cancer Lett 2003;190:191–197.
   PubMed Web of Science ®Google Scholar
• Oda Y, Ohishi Y, Basaki Y, et al Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expression. Cancer Sci 2007;98:1020–1026.
   PubMed Web of Science ®Google Scholar
• Kamura T, Yahata H, Amada S, et al Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma? Cancer 1999;85:2450–2454.
   PubMed Web of Science ®Google Scholar
• Shibahara K, Sugio K, Osaki T, et al Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 2001;7:3151–3155.
   PubMed Web of Science ®Google Scholar
• Oda Y, Ohishi Y, Saito T, et al Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma. J Pathol 2003;199:251–258.
   PubMed Web of Science ®Google Scholar
• Chatterjee M, Rancso C, Stuhmer T, et al The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Blood 2008;111:3714–3722.
   PubMed Web of Science ®Google Scholar
• Xu W, Zhou L, Qin R, Tang H, Shen H. Nuclear expression of YB-1 in diffuse large B-cell lymphoma: correlation with disease activity and patient outcome. Eur J Haematol 2009;83:313–319.
   PubMed Web of Science ®Google Scholar
• Oda Y, Kohashi K, Yamamoto H, et al Different expression profiles of Y-box-binding protein-1 and multidrug resistance-associated proteins between alveolar and embryonal rhabdomyosarcoma. Cancer Sci 2008;99:726–732.
   PubMed Web of Science ®Google Scholar
• Ohsawa M, Ikura Y, Fukushima H, et al Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma. Oncology 2005;68:422–431.
   PubMed Web of Science ®Google Scholar
• Andreadis C, Gimotty PA, Wahl P, et al Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma. Blood 2007;109:3409–3416.
   PubMed Web of Science ®Google Scholar
• Tay WL, Yip GW, Tan PH, et al Y-Box-binding protein-1 is a promising predictive marker of radioresistance and chemoradioresistance in nasopharyngeal cancer. Mod Pathol 2009;22:282–290.
   Google Scholar
• Stein H, Warnke RA, Chan WC, et al Diffuse large B-cell lymphoma, not otherwise specicified. Lyon: IARC; 2008.
   Google Scholar
• Lister TA, Crowther D, Sutcliffe SB, et al Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630–1636.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857–1861.
   PubMed Web of Science ®Google Scholar
• Seki R, Ohshima K, Fujisaki T, et al Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 2009;100:1842–1847.
   PubMed Web of Science ®Google Scholar
• Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Leppa S. Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. Mod Pathol 2009;22:1094–1101.
   PubMed Web of Science ®Google Scholar
• Ilic I, Mitrovic Z, Aurer I, et al Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab. Int J Hematol 2009;90:74–80.
   PubMed Web of Science ®Google Scholar
• Ghetie MA, Crank M, Kufert S, Pop I, Vitetta E. Rituximab but not other anti-CD20 antibodies reverses multidrug resistance in 2 B lymphoma cell lines, blocks the activity of P-glycoprotein (P-gp), and induces P-gp to translocate out of lipid rafts. J Immunother 2006;29:536–544.
   PubMed Web of Science ®Google Scholar
• Ranjan M, Tafuri SR, Wolffe AP. Masking mRNA from translation in somatic cells. Genes Dev 1993;7:1725–1736.
   PubMed Web of Science ®Google Scholar
• Sutherland BW, Kucab J, Wu J, et al Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 2005;24:4281–4292.
   PubMed Web of Science ®Google Scholar
• Stenina OI, Poptic EJ, DiCorleto PE. Thrombin activates a Y box-binding protein (DNA-binding protein B) in endothelial cells. J Clin Invest 2000;106:579–587.
   PubMed Web of Science ®Google Scholar
• Yasen M, Kajino K, Kano S, et al The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma. Clin Cancer Res 2005;11:7354–7361.
   PubMed Web of Science ®Google Scholar
• Ohashi S, Atsumi M, Kobayashi S. HSP60 interacts with YB-1 and affects its polysome association and subcellular localization. Biochem Biophys Res Commun 2009;385:545–550.
   PubMed Web of Science ®Google Scholar
• Rauen T, Raffetseder U, Frye BC, et al YB-1 acts as a ligand for Notch-3 receptors and modulates receptor activation. J Biol Chem 2009;284:26928–26940.
   PubMed Web of Science ®Google Scholar
• Chernov KG, Barbet A, Hamon L, Ovchinnikov LP, Curmi PA, Pastre D. Role of microtubules in stress granule assembly: microtubule dynamical instability favors the formation of micrometric stress granules in cells. J Biol Chem 2009;284:36569–36580.
   PubMed Web of Science ®Google Scholar
• Yuen AR, Sikic BI. Multidrug resistance in lymphomas. J Clin Oncol 1994;12:2453–2459.
   PubMed Web of Science ®Google Scholar
• Jerkeman M, Anderson H, Dictor M, Kvaloy S, Akerman M, Cavallin-Stahl E. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma–a Nordic Lymphoma Group study. Ann Hematol 2004;83:414–419.
   PubMed Web of Science ®Google Scholar
• Gascoyne RD, Rosenwald A, Poppema S, Lenz G. Prognostic biomarkers in malignant lymphomas. Leuk Lymphoma 2010;51(Suppl 1):9–11.
   Web of Science ®Google Scholar